BridgeBio Pharma CEO reports sales of 54,980 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported selling 54,980 common shares on November 18 and 19, 2026, through direct transactions and the Kumar Haldea Family Irrevocable Trust, of which he is a co-trustee. The sales were made under a Rule 10b5-1 plan adopted May 13, 2026.
Separate indirect holdings as of November 18 included 750,000 shares held by NK 2026 GRAT and 3,568,447 held by Kumar Haldea Revocable Trust. Kumar disclaims beneficial ownership of those trust-held shares except to the extent of his pecuniary interest.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F5, F4 | 8,500 | $78.3503 | $666K |
| Sale | Common Stock F1, F6, F4 | 1,500 | $79.293 | $119K |
| Sale | Common Stock F1, F2 | 4,490 | $76.9916 | $346K |
| Sale | Common Stock F1, F3 | 30,490 | $77.8271 | $2.37M |
| Sale | Common Stock F1, F2, F4 | 1,277 | $76.9915 | $98K |
| Sale | Common Stock F1, F3, F4 | 8,723 | $77.8269 | $679K |
| Holding | Common Stock F7 | -- | -- | -- |
| Holding | Common Stock F4 | -- | -- | -- |
Footnotes (7)
- F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
- F2. Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F3. Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F4. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
- F5. Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F6. Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
- F7. These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Key Figures
Key Terms
Rule 10b5-1 sales plan regulatory
weighted average sale price financial
grantor retained annuity trust financial
beneficial ownership regulatory
pecuniary interest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.